-
Notifications
You must be signed in to change notification settings - Fork 0
/
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non Small-Cell Lung Cancer An Individual Patient Data Meta-analysis.txt
2383 lines (2158 loc) · 220 KB
/
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non Small-Cell Lung Cancer An Individual Patient Data Meta-analysis.txt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
http://jnci.oxfordjournals.org/content/99/11/847.full
<!DOCTYPE html
PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
xmlns="http://www.w3.org/1999/xhtml"
xml:lang="en"
lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<title>Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual
Patient Data Meta-analysis
</title>
<meta name="googlebot" content="NOODP" />
<meta name="HW.ad-path" content="/cgi/content/full/99/11/847" />
<meta content="/jnci/99/11/847.atom" name="HW.identifier" />
<meta name="DC.Format" content="text/html" />
<meta name="DC.Language" content="en" />
<meta content="Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis"
name="DC.Title" />
<meta content="10.1093/jnci/djk196" name="DC.Identifier" />
<meta content="2007-06-06" name="DC.Date" />
<meta content="Oxford University Press" name="DC.Publisher" />
<meta content="Andrea Ardizzoni" name="DC.Contributor" />
<meta content="Luca Boni" name="DC.Contributor" />
<meta content="Marcello Tiseo" name="DC.Contributor" />
<meta content="Frank V. Fossella" name="DC.Contributor" />
<meta content="Joan H. Schiller" name="DC.Contributor" />
<meta content="Marianne Paesmans" name="DC.Contributor" />
<meta content="Davorin Radosavljevic" name="DC.Contributor" />
<meta content="Adriano Paccagnella" name="DC.Contributor" />
<meta content="Petr Zatloukal" name="DC.Contributor" />
<meta content="Paola Mazzanti" name="DC.Contributor" />
<meta content="Donald Bisset" name="DC.Contributor" />
<meta content="Rafael Rosell" name="DC.Contributor" />
<meta content="Journal of the National Cancer Institute"
name="citation_journal_title" />
<meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
<meta content="0027-8874" name="citation_issn" />
<meta content="1460-2105" name="citation_issn" />
<meta name="citation_author" content="Andrea Ardizzoni" />
<meta name="citation_author" content="Luca Boni" />
<meta name="citation_author" content="Marcello Tiseo" />
<meta name="citation_author" content="Frank V. Fossella" />
<meta name="citation_author" content="Joan H. Schiller" />
<meta name="citation_author" content="Marianne Paesmans" />
<meta name="citation_author" content="Davorin Radosavljevic" />
<meta name="citation_author" content="Adriano Paccagnella" />
<meta name="citation_author" content="Petr Zatloukal" />
<meta name="citation_author" content="Paola Mazzanti" />
<meta name="citation_author" content="Donald Bisset" />
<meta name="citation_author" content="Rafael Rosell" />
<meta content="Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis"
name="citation_title" />
<meta content="99" name="citation_volume" />
<meta content="11" name="citation_issue" />
<meta content="847" name="citation_firstpage" />
<meta content="857" name="citation_lastpage" />
<meta content="99/11/847" name="citation_id" />
<meta content="99/11/847" name="citation_id_from_sass_path" />
<meta content="jnci;99/11/847" name="citation_mjid" />
<meta content="10.1093/jnci/djk196" name="citation_doi" />
<meta content="http://jnci.oxfordjournals.org/content/99/11/847.abstract"
name="citation_abstract_html_url" />
<meta content="http://jnci.oxfordjournals.org/content/99/11/847.full"
name="citation_fulltext_html_url" />
<meta content="http://jnci.oxfordjournals.org/content/99/11/847.full.pdf"
name="citation_pdf_url" />
<meta content="/content/99/11.cover.gif" name="issue_cover_image" />
<meta content="http://jnci.oxfordjournals.org/content/99/11/847"
name="citation_public_url" />
<meta content="17551145" name="citation_pmid" />
<meta name="citation_section" content="Article" />
<meta name="robots" content="noarchive,nofollow" />
<meta name="googlebot" content="noarchive" />
<link href="/content/99/11/838.short" rel="prev" />
<link href="/content/99/11/858.short" rel="next" />
<link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
<link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/local/css/hw-local-global.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/publisher/css/hw-publisher-global.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/publisher/css/hw-publisher-ac.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/shared/css/hw-page-content.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/shared/css/jquery.fancybox-1.3.4.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/shared/css/hw-global-colexpand.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d29336306e1">var callbackToken='5378C25622D8400';</script><script type="text/javascript" id="session-d29336306e3">
var subCode='oupjournal_sub';
</script><script type="text/javascript">
var gAuthTimeStamp = '2015-10-27T12:13:12.864-07:00';
var gSessionId = 'gFGPJrCwWB21D3cex-XZZg';
var gAuthzRequired = 'false';
var gAuthnMethods1 = 'ip ip';
var gAuthnMethods2 = 'ip,ip';
var gAuthnIPs = '18.189.59.169,18.189.59.169';
var gAuthnIndividuals = '';
var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
</script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
MathJax.Hub.Config({
tex2jax: {
inlineMath: [["$","$"],["\\(","\\)"]],
processClass: "tex2jax_process|mathjax"
}
});
MathJax.Hub.Queue(function() {
gColTempResize = true;
fixColHeights(1);
gColTempResize = false;
});
</script><script type="text/javascript"
src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
var siqDOI = encodeURIComponent("10.1093/jnci/djk196");
var siqIsOpenAccess = encodeURIComponent("");
var siqPubDate = encodeURIComponent("20070606");
if (siqDOI.length == 0) {
siqDOI = "UNKNOWN";
}
if (gAuthnIndividuals.length != 0) {
if (gAuthnInstitutions.length != 0) {
authnEntity = encodeURIComponent(gAuthnIndividuals
+ ',' + gAuthnInstitutions);
} else {
authnEntity = encodeURIComponent(gAuthnIndividuals);
}
} else {
authnEntity = encodeURIComponent(gAuthnInstitutions);
}
var commonString =
'authSessionId=' + gSessionId + String.fromCharCode(0x26)
+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
+ 'authnInstitutions=' + authnEntity;
var gPageId = "pageid-content";
var gVariant = "full-text";
// Not completely done
var eventType = "full-text";
var accessType;
if (siqIsOpenAccess == 'true') {
accessType = 'SOA';
} else {
accessType = 'subscription';
}
var NTPT_PGEXTRA =
commonString + String.fromCharCode(0x26)
+ 'event_type=' + eventType + String.fromCharCode(0x26)
+ 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
+ 'access_type=' + accessType + String.fromCharCode(0x26)
+ 'doi=' + siqDOI ;
// alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/resource/css/h20-oup-header.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/resource/css/h20-oup-footer.css" />
<link rel="stylesheet" type="text/css" media="all"
href="/resource/css/h20-oup-sidebars.css" />
<link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
<link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
<link rel="stylesheet" type="text/css" media="screen"
href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
<body class="general_page journal jnci">
<div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
itemscope="itemscope"
itemtype="http://schema.org/ScholarlyArticle">
<noscript>
<p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
</noscript>
<p class="hide">
<a href="#content">Skip Navigation</a>
</p>
<div id="secondary_nav">
<strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
<ul>
<li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
<li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
<li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My
Account</span></a></li>
</ul>
</div>
<div id="header">
<h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
JNCI J Natl Cancer Inst
</span></a></h1>
</div>
<div id="primary_nav">
<ul>
<li id="nav_about_this_journal" title="About This Journal">
<a href="http://www.oxfordjournals.org/jnci/about.html">
<span>About This Journal</span>
</a>
</li>
<li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
<li id="nav_subscriptions" title="Subscriptions">
<a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
<span>Subscriptions</span>
</a>
</li>
<li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
<li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
<li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
</ul>
</div>
<div id="user_nav">
<div class="header-ac-elements">
<div id="authstring">
<ul>
<li class="subscr-ref">Institution: MIT Libraries</li>
<li class="no-left-border">
<a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F99%2F11%2F847.full">
Sign In as Personal Subscriber
</a>
</li>
</ul>
</div>
</div>
</div>
<ul id="site-breadcrumbs">
<li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
<li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
class="breadcrumb_subject">Medicine & Health</a></span></li>
<li><a href="/">JNCI J Natl Cancer Inst</a></li>
<li><a href="/content/99/11.toc">
<span xmlns="" class="volume-value">Volume 99</span>
<span xmlns="" class="issue-value"> Issue 11</span></a></li>
<li>Pp. <span class="slug-pages">
847-857.
</span></li>
</ul>
<div id="oas_top" class="ad_hidden">
<iframe id="id_advertframe_top"
src="/resource/htmlfiles/advert.html?p=Top&u=jnci.oxfordjournals.org/content/99/11/847.full"
width="0"
height="0"
frameborder="0"
scrolling="no"
class="resize_ad"></iframe>
</div>
<a name="content"></a>
<div id="h20_page"></div>
<div id="content-block">
<div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual
Patient Data Meta-analysis
</h1>
<div class="contributors">
<ol class="contributor-list" id="contrib-group-1">
<li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Andrea+Ardizzoni&sortspec=date&submit=Submit">Andrea Ardizzoni</a></span>,
</li>
<li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Luca+Boni&sortspec=date&submit=Submit">Luca Boni</a></span>,
</li>
<li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Marcello+Tiseo&sortspec=date&submit=Submit">Marcello Tiseo</a></span>,
</li>
<li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Frank+V.+Fossella&sortspec=date&submit=Submit">Frank V. Fossella</a></span>,
</li>
<li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Joan+H.+Schiller&sortspec=date&submit=Submit">Joan H. Schiller</a></span>,
</li>
<li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Marianne+Paesmans&sortspec=date&submit=Submit">Marianne Paesmans</a></span>,
</li>
<li class="contributor" id="contrib-7" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Davorin+Radosavljevic&sortspec=date&submit=Submit">Davorin Radosavljevic</a></span>,
</li>
<li class="contributor" id="contrib-8" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Adriano+Paccagnella&sortspec=date&submit=Submit">Adriano Paccagnella</a></span>,
</li>
<li class="contributor" id="contrib-9" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Petr+Zatloukal&sortspec=date&submit=Submit">Petr Zatloukal</a></span>,
</li>
<li class="contributor" id="contrib-10" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Paola+Mazzanti&sortspec=date&submit=Submit">Paola Mazzanti</a></span>,
</li>
<li class="contributor" id="contrib-11" itemprop="author" itemscope="itemscope"
itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
href="/search?author1=Donald+Bisset&sortspec=date&submit=Submit">Donald Bisset</a></span> and
</li>
<li class="last" id="contrib-12"><span class="name"><a class="name-search"
href="/search?author1=Rafael+Rosell&sortspec=date&submit=Submit">Rafael Rosell</a></span></li>
<li class="on-behalf-of"> For the CISCA (CISplatin versus CArboplatin) Meta-analysis Group</li>
</ol>
<ol class="affiliation-list">
<li class="aff"><a id="aff-1" name="aff-1"></a><address><strong>Affiliations of authors</strong>: Division of Medical Oncology, University Hospital, Parma, Italy (AA, MT); Unit of Clinical Trials, National Institute for
Cancer Research, Genova, Italy (LB); Department of Thoracic/Head and Neck Medical Oncology, M.D. Anderson Cancer Center, Houston,
TX (FVF); Eastern Cooperative Oncology Group, Division of Hematology/Oncology, University of Texas Southwestern, Dallas, TX
(JHS); European Lung Cancer Working Party, Data Centre, Institut Jules Bordet, Bruxelles, Belgium (MP); Department of Medical
Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia and Montenegro (DR); Gruppo di Studio Tumori Polmonari
del Veneto, Division of Medical Oncology, SS Giovanni e Paolo Hospital, Venezia, Italy (AP); Charles University and Institute
of Postgraduate Studies, Prague, Faculty Hospital Na Bulovce, Prague, Czech Republic (PZ); Division of Medical Oncology, Umberto
I University Hospital, Ancona, Italy (PM); Department of Oncology, Grampian University Hospitals, Aberdeen, UK (DB); Medical
Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias I Pujol, Barcelona, Spain (RR)
</address>
</li>
</ol>
<ol class="corresp-list">
<li class="fn" id="corresp-1"><strong>Correspondence to:</strong><br /> Andrea Ardizzoni, MD, Division of Medical Oncology, University Hospital, Via Gramsci 14, 43100 Parma, Italy (e-mail: <span class="em-link"><span class="em-addr">aardizzoni{at}ao.pr.it</span></span>)
</li>
</ol>
<ul class="history-list">
<li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
hwp:start="2006-10-17"><span class="received-label">Received </span>October 17, 2006.
</li>
<li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
hwp:start="2007-03-28"><span class="rev-recd-label">Revision received </span>March 28, 2007.
</li>
<li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
hwp:start="2007-04-27"><span class="accepted-label">Accepted </span>April 27, 2007.
</li>
</ul>
</div>
<div class="section abstract" id="abstract-1" itemprop="description">
<div class="section-nav">
<div class="nav-placeholder"> </div><a href="#sec-11" title="Materials and Methods" class="next-section-link"><span>Next Section</span></a></div>
<h2>Abstract</h2>
<div id="sec-1" class="subsection">
<p id="p-1"><strong>Background</strong> Because the efficacy of carboplatin and cisplatin in the treatment of advanced non–small-cell lung cancer (NSCLC) has not
been proven to be equivalent, an individual patient data meta-analysis comparing the two treatments was performed.
</p>
</div>
<div id="sec-2" class="subsection">
<p id="p-2"><strong>Methods</strong> Randomized trials comparing carboplatin to cisplatin in first-line treatment of advanced NSCLC were identified and their
electronic databases obtained. A general variance-based method was used to estimate the summary hazard ratios (HRs), odds
ratios (ORs), and their 95% confidence intervals (CIs) for mortality, objective response, and toxicity. Cochran's chi-square
test (<em>Q</em> test) was used to test for heterogeneity among trials, and the <em>I<sup> 2</sup></em> index, which expresses the proportion of variability of the results due to heterogeneity, was calculated. A random-effects
model that takes into account interstudy variation was also applied. All statistical tests were two-sided.
</p>
</div>
<div id="sec-3" class="subsection">
<p id="p-3"><strong>Results</strong> Nine trials that included a total of 2968 patients were analyzed; overall median follow-up was 1021 days. The objective response
rate was higher for patients treated with cisplatin than for patients treated with carboplatin (30% versus 24%, respectively;
OR = 1.37; 95% CI = 1.16 to 1.61; <em>P</em><.001). Carboplatin treatment was associated with a non–statistically significant increase in the hazard of mortality relative
to treatment with cisplatin (HR = 1.07; 95% CI = 0.99 to 1.15; <em>P</em> = .100). In patients with nonsquamous tumors and those treated with third-generation chemotherapy, carboplatin-based chemotherapy
was associated with a statistically significant increase in mortality (HR = 1.12; 95% CI = 1.01 to 1.23 and HR = 1.11; 95%
CI = 1.01 to 1.21, respectively). Cisplatin-based chemotherapy was associated with more severe nausea and vomiting and nephrotoxicity;
severe thrombocytopenia was more frequent during carboplatin-based chemotherapy.
</p>
</div>
<div id="sec-4" class="subsection">
<p id="p-4"><strong>Conclusions</strong> Our individual patient data meta-analysis suggests that cisplatin-based chemotherapy is slightly superior to carboplatin-based
chemotherapy in terms of response rate and, in certain subgroups, in prolonging survival without being associated with an
increase in severe toxic effects. Therefore, cisplatin-based third-generation regimens should remain the standard reference
for the treatment of selected patients with advanced-stage NSCLC and of those with earlier-stage disease.
</p>
</div>
</div>
<p id="p-5">
<div class="boxed-text" id="boxed-text-1">
<div id="sec-5" class="subsection">
<h4>Context and Caveats</h4>
<div id="sec-6" class="subsection">
<h5>Prior knowledge</h5>
<p id="p-6">Platinum-based chemotherapy leads to a small but statistically significant improvement in survival in patients with advanced
non–small-cell lung cancer. Carboplatin had largely replaced cisplatin as the platinum-containing drug used to treat this
disease because it was associated with a lower incidence of serious side effects. However, it was unclear whether the two
drugs had similar clinical efficacy in the treatment of non–small-cell lung cancer.
</p>
</div>
<div id="sec-7" class="subsection">
<h5>Study design</h5>
<p id="p-7">A meta-analysis of individual patient data from randomized controlled clinical trials that compared chemotherapy regimens
containing either cisplatin or carboplatin.
</p>
</div>
<div id="sec-8" class="subsection">
<h5>Contribution</h5>
<p id="p-8">This study presented evidence that cisplatin was more effective than carboplatin in patients treated with newer chemotherapy
regimens and in patients with nonsquamous tumors. The side effects associated with the two drugs in non–small-cell lung cancer
patients were clarified.
</p>
</div>
<div id="sec-9" class="subsection">
<h5>Limitations</h5>
<p id="p-9">The conclusions are based on a somewhat heterogeneous group of clinical trials, some of which were small.</p>
</div>
<div id="sec-10" class="subsection">
<h5>Implications</h5>
<p id="p-10">Cisplatin may well be preferable to carboplatin in non–small-cell lung cancer patients whose disease is at an early stage
and in those patients who have advanced disease with a relatively good prognosis.
</p>
</div>
</div>
</div>
</p>
<p id="p-11">Approximately one-third of all cancer-related deaths in Western countries are due to lung cancer. Non–small-cell lung cancer
(NSCLC) represents 75%–80% of lung cancer cases and accounts for approximately 1.2 million new cases worldwide each year (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>). Disappointingly, the 5-year survival rate is only about 15%, due to the high rate of unresectable disease at diagnosis
and to the inability of chemotherapy to cure metastatic disease.
</p>
<p id="p-12">The majority of patients with NSCLC have advanced disease at diagnosis and are therefore potential candidates for systemic
therapy. Several prospective trials and meta-analyses were required to prove convincingly that chemotherapy leads to a small
but statistically significant improvement in survival when compared with best supportive care only. In the meta-analysis by
the Non–Small-Cell Lung Cancer Collaborative Group, a reduction in mortality (hazard ratio [HR] = 0.73) was observed with
an absolute improvement of 10% in 1-year survival when platinum-based chemotherapy was compared with best supportive care
(<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>). Furthermore, randomized studies of chemotherapy versus best supportive care have shown that chemotherapy reduces cancer-related
symptoms and does not compromise quality of life (<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>).
</p>
<p id="p-13">A number of recent randomized studies have demonstrated that the addition of platinum to any one of a number of other single
agents resulted in an improved outcome compared with the single agent alone and that the introduction of third-generation
drugs, such as gemcitabine, taxanes, and vinorelbine, in conjunction with platinum further improved chemotherapy results in
advanced NSCLC (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>). On the basis of these data, recent American (<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>), Canadian (<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>), and European (<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>) guidelines for the treatment of advanced NSCLC recommend platinum-based third-generation chemotherapy doublets as standard
of care for first-line treatment.
</p>
<p id="p-14">Despite its pivotal role in NSCLC management, treatment with cisplatin is associated with a number of serious and unpleasant
side effects, including nausea and vomiting, myelosuppression, neurotoxicity, and renal function impairment, and it is burdened
by delivery problems, such as the need for prolonged hydration and hospitalization (<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>). To overcome these limitations, most clinicians now use the cisplatin analog carboplatin, which is associated with a lower
incidence of neurotoxicity, nephrotoxicity, and nausea and vomiting compared with cisplatin and does not require prolonged
hydration (<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>).
</p>
<p id="p-15">Although carboplatin and cisplatin have similar mechanisms of action and preclinical activity spectra, it is unclear whether
their clinical efficacy is the same for all tumor types. Although for some tumors, such as ovarian cancer, equivalent efficacy
has been convincingly proven, for others, such as germ cell and head–neck tumors, there is evidence for the inferiority of
carboplatin compared with cisplatin (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>).
</p>
<p id="p-16">Nearly 3000 NSCLC patients were enrolled in several randomized trials to determine whether carboplatin or cisplatin is more
effective in treating NSCLC. The results from these trials were conflicting, and therefore, it is still debated whether it
is justified to replace cisplatin with carboplatin in standard practice (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>–<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>). The use of carboplatin-based regimens is considered to be standard of care for NSCLC in the United States (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>), whereas cisplatin-based regimens are generally preferred in Europe (<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>).
</p>
<p id="p-17">To compare efficacy of cisplatin and carboplatin in the first-line chemotherapy treatment of advanced NSCLC with sufficient
statistical power, we conducted an individual patient data meta-analysis (CISCA project [cisplatin versus carboplatin meta-analysis
in advanced NSCLC]) on all patients enrolled in randomized studies comparing the effectiveness of these two platinum agents.
</p>
<div class="section" id="sec-11">
<div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-16" title="Results" class="next-section-link"><span>Next Section</span></a></div>
<h2>Materials and Methods</h2>
<div id="sec-12" class="subsection">
<h3>Search for Trials</h3>
<p id="p-18">We searched all published (as English-language full paper or abstract) and unpublished randomized trials that compared cisplatin
with carboplatin in the first-line treatment of advanced NSCLC. Searches were conducted by 1) regular computer-aided searches
of MEDLINE or CANCERLIT literature databases; 2) examining reference lists of published trials, review articles, and bibliographies
of relevant oncology books; 3) searching meeting abstracts; 4) consulting the US National Cancer Institute (NCI) Physicians
Data Query Clinical Protocol; and 5) contacting individual trialists or cooperative research groups. For databases research,
the following strategies were used: “Cisplatin [MeSH] AND Carboplatin [MeSH] AND Carcinoma, Non-small-cell lung/drug therapy
[MeSH] AND Clinical trial [pt]” and “Cisplatin AND Carboplatin AND Non-small cell lung cancer.”
</p>
</div>
<div id="sec-13" class="subsection">
<h3>Selection of Trials</h3>
<p id="p-19">Trials had to fulfill the following inclusion criteria: 1) patients were randomly assigned to treatment; 2) cisplatin and
carboplatin were compared in first-line chemotherapy without confounding by additional agents or interventions (i.e., in the
combination chemotherapy, the control and experimental arms had to differ only by cisplatin or carboplatin component); and
3) only patients with diagnosis of NSCLC were included.
</p>
</div>
<div id="sec-14" class="subsection">
<h3>Individual Patient Data Collection</h3>
<p id="p-20">The computer files containing the individual patients records including study identification acronym, patient identification
number, date of birth, sex, performance status, histology, stage at random assignment, date of randomization, treatment arm,
total number of administered cycles, best overall response, worst toxicity (hematologic, nausea and vomiting, neurotoxicity,
or nephrotoxicity), date of last observation, and status at last observation were requested from the principal investigators.
To avoid potential bias, information for all randomly assigned patients, including those who had been excluded from the final
analysis, was required.
</p>
<p id="p-21">Data were collected and analyzed at the Trial Office of National Institute for Cancer Research of Genova, Italy. All data
received were checked to ensure both the accuracy of the meta-analysis database and the quality of randomization and follow-up.
The study coordinator of each trial had to resolve any computer-generated query. The study protocol was approved by the Ethical
Committee and Review Board of the coordinating institution.
</p>
</div>
<div id="sec-15" class="subsection">
<h3>Statistical Analysis</h3>
<p id="p-22">The primary endpoint in the meta-analysis was overall survival, defined as the time elapsing from random assignment until
death from any cause. Living patients were censored at the date of last follow-up. The secondary endpoints were overall response
rate, defined as the sum of partial and complete response rates (according to World Health Organization criteria), and toxicity,
which was graded according to NCI Common Toxicity Criteria (CTC).
</p>
<p id="p-23">All analyses were conducted on an intention-to-treat basis, and all randomly assigned patients were included in the analyses
according to the allocated treatment. A general variance-based method was used to estimate the summary hazard ratios (HRs),
odds ratios (ORs), and their 95% confidence intervals (CIs) (<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>,<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>). Ratios were uniformly expressed relative to patients who received cisplatin therapy. The global null hypothesis that the
treatment difference in all studies is equal to 0 was tested by comparing the <em>U</em> statistic with the chi-square distribution with 1 df (<a id="xref-ref-17-2" class="xref-bibr" href="#ref-17">17</a>). Cochran's chi-square test (<em>Q</em> test) was used to test for the presence of heterogeneity among trials (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>). Moreover, the <em>I</em><sup> 2</sup> index, which expresses as a percentage the proportion of variability of the results due to heterogeneity as opposed to sampling
error, was calculated (<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>). Based on the statistical significance of the <em>Q</em> test, we applied a random-effects model, which allows the meta-analysis to take into account interstudy variation. In particular,
the random-effects survival model was implemented with a frequentist approach fitting a Cox model with a frailty term (<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>). The variance of the Gaussian random-effects distribution was based on an approximate restricted maximum likelihood estimation
(<a id="xref-ref-20-2" class="xref-bibr" href="#ref-20">20</a>). Median follow-up time was estimated by the reverse Kaplan–Meier method (<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>).
</p>
<p id="p-24">The following factors were identified in the protocol of the study to plan the subgroup analyses: age (<65 versus ≥65 years),
stage of disease (IIIB versus IV), performance status (0–1 versus 2), and histology (squamous versus nonsquamous). In the
analyses, an additional variable (second- versus third-generation chemotherapy regimen) was considered, although it was not
previously specified, based on the results of two meta-analyses that used abstracted data (<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>,<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>). Before the subgroup analyses, regression models were used to evaluate the statistical significance of the interaction between
the treatment and the potential prognostic factors. These models included a Cox model stratified by trials, for time-to-event
outcomes, and a logistic regression model with trial indicator variables, for binary outcomes (<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>).
</p>
<p id="p-25">All statistical analyses were conducted with SAS for Windows version 9.1 (Cary, NC) and R (<a href="http://www.r-project.org">http://www.r-project.org</a>). All statistical tests were two-sided, and <em>P</em> values of .05 or less were considered to be statistically significant, except for the test for interaction; in this case,
due to the explanatory purpose of the analyses, a cutoff equal to .10 was chosen.
</p>
</div>
</div>
<div class="section" id="sec-16">
<div class="section-nav"><a href="#sec-11" title="Materials and Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-20" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
<h2>Results</h2>
<p id="p-26">Nine eligible trials (<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>–<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>) were identified, and the respective electronic data bases were obtained for all of them. The analysis was conducted on the
individual data of the 2968 patients with advanced NSCLC (stage IIIB–IV) enrolled in the nine trials and randomly assigned
to receive chemotherapy with cisplatin (1489 patients) or with carboplatin (1479 patients), respectively.
</p>
<p id="p-27">Of the nine trials, seven were randomized phase III trials (<a id="xref-ref-25-2" class="xref-bibr" href="#ref-25">25</a>,<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a>,<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>–<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-33-2" class="xref-bibr" href="#ref-33">33</a>), and the remaining two were randomized phase II trials (<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>,<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>). None was a placebo-controlled, double-blind trial. Three trials included second-generation chemotherapy regimens: etoposide
(<a id="xref-ref-25-3" class="xref-bibr" href="#ref-25">25</a>), mitomycin and vindesine (<a id="xref-ref-26-2" class="xref-bibr" href="#ref-26">26</a>), and mitomycin and vinblastine (<a id="xref-ref-33-3" class="xref-bibr" href="#ref-33">33</a>). Five investigated third-generation chemotherapy doublets: cisplatin or carboplatin with paclitaxel (<a id="xref-ref-28-2" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>), docetaxel (<a id="xref-ref-31-2" class="xref-bibr" href="#ref-31">31</a>), or gemcitabine (<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-2" class="xref-bibr" href="#ref-32">32</a>). One trial compared cisplatin and carboplatin when they were used in combination with tirapazamine (<a id="xref-ref-27-2" class="xref-bibr" href="#ref-27">27</a>). Two of the nine trials included other treatment arms, in addition to the two arms considered for the meta-analysis (<a id="xref-ref-29-2" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-31-3" class="xref-bibr" href="#ref-31">31</a>). In the Eastern Cooperative Oncology Group (ECOG) 1594 trial, cisplatin–gemcitabine and cisplatin–docetaxel combinations
were also studied (<a id="xref-ref-29-3" class="xref-bibr" href="#ref-29">29</a>), and in the TAX326 study, some patients were randomly assigned to a cisplatin–vinorelbine arm (<a id="xref-ref-31-4" class="xref-bibr" href="#ref-31">31</a>). Cisplatin dose was 75 mg/m<sup>2</sup> in three trials (<a id="xref-ref-27-3" class="xref-bibr" href="#ref-27">27</a>,<a id="xref-ref-29-4" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-31-5" class="xref-bibr" href="#ref-31">31</a>), 80 mg/m<sup>2</sup> in three others (<a id="xref-ref-28-3" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-30-2" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-3" class="xref-bibr" href="#ref-32">32</a>), 100 mg/m<sup>2</sup> in one trial (<a id="xref-ref-33-4" class="xref-bibr" href="#ref-33">33</a>), and 120 mg/m<sup>2</sup> in two (<a id="xref-ref-25-4" class="xref-bibr" href="#ref-25">25</a>,<a id="xref-ref-26-3" class="xref-bibr" href="#ref-26">26</a>). For carboplatin, the dose was expressed in mg/m<sup>2</sup> in three trials; the doses were 325 (<a id="xref-ref-25-5" class="xref-bibr" href="#ref-25">25</a>), 500 mg/m<sup>2</sup> (<a id="xref-ref-26-4" class="xref-bibr" href="#ref-26">26</a>), and 300 mg/m<sup>2</sup> (<a id="xref-ref-33-5" class="xref-bibr" href="#ref-33">33</a>). Carboplatin dose was expressed according to Calvert formula (<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>) as area under the curve (AUC) in the other six trials; the AUC equaled 6 in four studies (<a id="xref-ref-27-4" class="xref-bibr" href="#ref-27">27</a>–<a id="xref-ref-29-5" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-31-6" class="xref-bibr" href="#ref-31">31</a>), and 5 in the other two trials (<a id="xref-ref-30-3" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-4" class="xref-bibr" href="#ref-32">32</a>).
</p>
<p id="p-28">In the nine trials included in the meta-analysis, patient characteristics were well balanced between the cisplatin and carboplatin
treatments (<a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>), such that overall the set of patients treated with cisplatin and those treated with carboplatin had the same median age
(60 years), proportion of males (76%), and proportion of patients with performance status between 0 and 1 (86%). The proportions
of patients with stage IV disease were 68% and 69% in the cisplatin and carboplatin arms, respectively, and the proportion
of patients with squamous histology was slightly more than one-third in both arms. A median of four cycles was administered
for both cisplatin (range 0–15) and carboplatin (range 0–22).
</p>
<div class="table pos-float" id="T1">
<div class="table-inline">
<div class="callout"><span>View this table:</span><ul class="callout-links">
<li><a href="847/T1.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/T1.expansion.html">In a new window</a></li>
</ul>
</div>
</div>
<div class="table-caption"><span class="table-label">Table 1</span>
<p id="p-29" class="first-child">Characteristics of patients enrolled in the nine trials included in the meta-analysis*</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
<div id="sec-17" class="subsection">
<h3>Survival</h3>
<p id="p-31">Survival data were available from all nine studies (<a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a>). The overall median follow-up was 1021 days. Cisplatin-treated patients had a median survival of 9.1 months and a 1-year
survival probability of 37%, while carboplatin-treated patients had a median survival of 8.4 months and a 1-year survival
probability of 34% (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1</a>). The risk of death was higher with carboplatin compared with cisplatin, although the difference was not statistically significant
(HR = 1.07, 95% CI = 0.99 to 1.15, <em>P</em> = .100) (<a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 2</a>). Moreover, there was statistically significant heterogeneity between treatment effects on mortality among the trials (<em>Q</em> test = 17.03, <em>P</em> = .030), and the <em>I <sup>2</sup></em> index indicated that 52% of the variability across trials was due to heterogeneity rather than chance. The random-effects
survival model gave an estimated value of the hazard ratio of mortality equal to 1.08 (95% CI = 1.00 to 1.16, <em>P</em> = .063).
</p>
<div class="table pos-float" id="T2">
<div class="table-inline">
<div class="callout"><span>View this table:</span><ul class="callout-links">
<li><a href="847/T2.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/T2.expansion.html">In a new window</a></li>
</ul>
</div>
</div>
<div class="table-caption"><span class="table-label">Table 2</span>
<p id="p-32" class="first-child">Survival in the nine trials included in the meta-analysis*</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
<div id="F1" class="fig pos-float odd">
<div class="fig-inline"><a href="847/F1.expansion.html"><img alt="Fig. 1" src="847/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
<li><a href="847/F1.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/F1.expansion.html">In a new window</a></li>
</ul>
<ul class="fig-services">
<li class="ppt-link"><a href="/powerpoint/99/11/847/F1">Download as PowerPoint Slide</a></li>
</ul>
</div>
</div>
<div class="fig-caption"><span class="fig-label">Fig. 1</span>
<p id="p-36" class="first-child">Kaplan–Meier <strong>curves</strong> and <strong>error bars</strong> showing 95% confidence intervals of overall survival for cisplatin- and carboplatin-based chemotherapies.
</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
<div id="F2" class="fig pos-float odd">
<div class="fig-inline"><a href="847/F2.expansion.html"><img alt="Fig. 2" src="847/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
<li><a href="847/F2.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/F2.expansion.html">In a new window</a></li>
</ul>
<ul class="fig-services">
<li class="ppt-link"><a href="/powerpoint/99/11/847/F2">Download as PowerPoint Slide</a></li>
</ul>
</div>
</div>
<div class="fig-caption"><span class="fig-label">Fig. 2</span>
<p id="p-37" class="first-child">Overall survival of carboplatin- versus cisplatin-based chemotherapy. To describe the effect of carboplatin on mortality,
the log-rank statistic (the observed minus the expected number of deaths) and its variance were computed for each trial. Combining
these statistics, the event rate ratios of all trials and their weighted average were calculated with 95% confidence intervals
(CIs). The test statistics <em>U</em> and <em>Q</em> were used for hypothesis testing about treatment difference and presence of heterogeneity across studies, respectively. The
summary hazard ratio was 1.07 (95% CI = 0.99 to 1.15, <em>P</em> = .100).
</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
<p id="p-38">The same test for heterogeneity was performed after omitting the study by Jelic at al. (<a id="xref-ref-26-7" class="xref-bibr" href="#ref-26">26</a>), the only one showing a statistically significant advantage of carboplatin over cisplatin. With this omission, the result
of the <em>Q</em> test was not statistically significant (<em>P</em> = .418), and the value of <em>I<sup> 2</sup></em> index decreased to 1%, indicating that most of heterogeneity in the meta-analysis was related to this single study.
</p>
<p id="p-39">In the subgroup analyses (these included all nine studies) according to age (<65 versus ≥65 years), stage of disease (IIIB
versus IV), performance status (0–1 versus 2), histology (squamous versus nonsquamous), and type of chemotherapy regimen (second-
versus third-generation), the test for interaction between the treatment and the different variables reached statistical significance
for histology and for the type of regimen (<em>P</em> = .098 and <em>P</em> = .093, respectively) (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 3</a>). In the different subgroups, we calculated the hazard ratio for mortality from all causes for patients treated with carboplatin
relative to those treated with cisplatin. Based on these analyses, the hazard ratio for mortality in patients with nonsquamous
NSCLC was 1.12 (95% CI = 1.01 to 1.23), whereas in the subgroup with squamous histology, it was 0.97 (95% CI = 0.85 to 1.10).
The hazard ratios for mortality were 0.94 (95% CI = 0.80 to 1.11) and 1.11 (95% CI = 1.01 to 1.21) in the subgroups of patients
treated with second- and third-generation regimens, respectively. Third-generation regimens were administered to 2330 patients,
80% of the total population.
</p>
<div id="F3" class="fig pos-float odd">
<div class="fig-inline"><a href="847/F3.expansion.html"><img alt="Fig. 3" src="847/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
<li><a href="847/F3.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/F3.expansion.html">In a new window</a></li>
</ul>
<ul class="fig-services">
<li class="ppt-link"><a href="/powerpoint/99/11/847/F3">Download as PowerPoint Slide</a></li>
</ul>
</div>
</div>
<div class="fig-caption"><span class="fig-label">Fig. 3</span>
<p id="p-40" class="first-child"> Hazard ratios for mortality and their 95% confidence intervals of carboplatin- versus cisplatin-based chemotherapy for each
of the patient subgroups examined.
</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
</div>
<div id="sec-18" class="subsection">
<h3>Response Rate</h3>
<p id="p-41">Data about objective response were available for all nine studies (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>). Overall, 2669 patients, 1326 treated with cisplatin and 1343 with carboplatin, were assessable for response. (According
to the intention-to-treat principle, nonassessable patients were considered as nonresponders.) The response rates (complete
plus partial responses according to the World Health Organization criteria) were 30% for cisplatin and 24% for carboplatin,
respectively, with an odds ratio for nonresponse (among patients treated with carboplatin versus those treated with cisplatin)
of 1.37 (95% CI = 1.16 to 1.61; <em>P</em><.001) (<a id="xref-fig-4-1" class="xref-fig" href="#F4">Fig. 4</a>). The result of the test for heterogeneity among the studies was not statistically significant (<em>Q</em> test = 4.13; <em>P</em> = .845), and the <em>I<sup> 2</sup></em> index (0%) indicated that variability across trials was due to chance rather than heterogeneity.
</p>
<div class="table pos-float" id="T3">
<div class="table-inline">
<div class="callout"><span>View this table:</span><ul class="callout-links">
<li><a href="847/T3.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/T3.expansion.html">In a new window</a></li>
</ul>
</div>
</div>
<div class="table-caption"><span class="table-label">Table 3</span>
<p id="p-42" class="first-child">Response rate in the nine trials included in the meta-analysis*</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
<div id="F4" class="fig pos-float odd">
<div class="fig-inline"><a href="847/F4.expansion.html"><img alt="Fig. 4" src="847/F4.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
<li><a href="847/F4.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/F4.expansion.html">In a new window</a></li>
</ul>
<ul class="fig-services">
<li class="ppt-link"><a href="/powerpoint/99/11/847/F4">Download as PowerPoint Slide</a></li>
</ul>
</div>
</div>
<div class="fig-caption"><span class="fig-label">Fig. 4</span>
<p id="p-45" class="first-child">Response rate of carboplatin- versus cisplatin-based chemotherapy. To describe effect of carboplatin on objective response,
the observed minus the expected number of nonresponder patient statistic and its variance was computed for each trial. Combining
these statistics, the odds ratios of the trials and their weighted average were calculated with 95% confidence intervals (CIs).
The test statistics <em>U</em> and <em>Q</em> were used for hypothesis testing about treatment difference and presence of heterogeneity across studies, respectively. The
summary odds ratio was 1.37 (95% CI = 1.16 to 1.61, <em>P</em><.001).
</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
<p id="p-46">In the subgroup analyses (these included all nine studies) according to age (<65 versus ≥65 years), stage of disease (IIIB
versus IV), performance status (0–1 versus 2), histology (squamous versus nonsquamous), and type of chemotherapy regimen (second-
versus third-generation), the result of the interaction test between the treatment and the different variables was statistically
significant only when patients were categorized according to histology (<em>P</em> = .046). The odds ratio was 1.58 (95% CI = 1.27 to 1.97) in the subgroup of the patients with nonsquamous histology, whereas
it was 1.10 (95% CI = 0.85 to 1.43) in the subgroup with squamous histology.
</p>
</div>
<div id="sec-19" class="subsection">
<h3>Toxicity</h3>
<p id="p-47">Data as to the frequency of NCI-CTC grade 3–4 hematologic and nonhematologic toxic effects were available for eight of the
nine studies. Patients treated with carboplatin were more likely to experience thrombocytopenia compared with patients treated
with cisplatin (OR = 2.27, 95% CI = 1.71 to 3.01, <em>P</em><.001), whereas the frequencies of leucopenia (OR = 0.96, 95% CI = 0.81 to 1.14, <em>P</em> = .644), neutropenia (OR = 0.95, 95% CI = 0.80 to 1.12, <em>P</em> = .520), and anemia (OR = 1.10, 95% CI = 0.87 to 1.40, <em>P</em> = .424) were the same in those treated with cisplatin compared with those who received carboplatin (<a id="xref-table-wrap-4-1" class="xref-table" href="#T4">Table 4</a>). Cisplatin-based chemotherapy caused more nausea and vomiting than that based on carboplatin (OR = 0.42, 95% CI = 0.33 to
0.53, <em>P</em><.001) and renal toxicity (OR = 0.37, 95% CI = 0.15 to 0.88, <em>P</em> = .018). The incidence of neurotoxicity was not different in the two treatments groups (OR = 0.96, 95% CI = 0.75 to 1.23,
<em>P</em> = .758) (<a id="xref-table-wrap-5-1" class="xref-table" href="#T5">Table 5</a>).
</p>
<div class="table pos-float" id="T4">
<div class="table-inline">
<div class="callout"><span>View this table:</span><ul class="callout-links">
<li><a href="847/T4.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/T4.expansion.html">In a new window</a></li>
</ul>
</div>
</div>
<div class="table-caption"><span class="table-label">Table 4</span>
<p id="p-48" class="first-child">Grade 3–4 (according to National Cancer Institute Common Toxicity Criteria) hematologic toxicity in eight of the nine trials
included in the meta-analysis*
</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
<div class="table pos-float" id="T5">
<div class="table-inline">
<div class="callout"><span>View this table:</span><ul class="callout-links">
<li><a href="847/T5.expansion.html">In this window</a></li>
<li><a class="in-nw" href="847/T5.expansion.html">In a new window</a></li>
</ul>
</div>
</div>
<div class="table-caption"><span class="table-label">Table 5</span>
<p id="p-52" class="first-child">Grade 3–4 (according to National Cancer Institute Common Toxicity Criteria) nonhematologic (nausea and vomiting, neurotoxicity,
and nephrotoxicity) toxicity in eight of the nine trials included in the meta-analysis*
</p>
<div class="sb-div caption-clear"></div>
</div>
</div>
</div>
</div>
<div class="section" id="sec-20">
<div class="section-nav"><a href="#sec-16" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
<h2>Discussion</h2>
<p id="p-56">The results of this meta-analysis provide evidence that carboplatin-based combination chemotherapy is inferior to therapy
based on cisplatin in terms of the rate of objective response (OR for no response = 1.37, 95% CI = 1.16 to 1.61, <em>P</em><.001). Carboplatin-based chemotherapy appeared slightly less effective in prolonging survival, although overall the difference
was not statistically significant (HR of death = 1.07, 95% CI = 0.99 to 1.15, <em>P</em> = .100). However, when the analysis was restricted to the 2330 patients who were treated with third-generation platinum-based
regimens in more recent trials, treatment with cisplatin was associated with a statistically significant improvement in survival
compared with treatment based on carboplatin (HR of mortality with carboplatin relative to cisplatin = 1.11, 95% CI = 1.01
to 1.21). Similarly, when the analysis was restricted to patients with nonsquamous histology, treatment with cisplatin was
superior, in terms of survival, to treatment with carboplatin (HR = 1.12, 95% CI = 1.01 to 1.23).
</p>
<p id="p-57">The most likely explanation for the achievement of statistical significance in the third-generation chemotherapy and the nonsquamous
histology subgroups is that heterogeneity was eliminated in the subgroup analysis. In the analyses of those patients with
nonsquamous NSCLC and those who received third-generation chemotherapies, the trial reported by Jelic et al. (<a id="xref-ref-26-11" class="xref-bibr" href="#ref-26">26</a>) was not included because it was restricted to patients with squamous histology and it used a second-generation regimen.
This study from Serbia, which is the only one that showed statistically significant superiority of carboplatin, was the source
of most of the heterogeneity in the meta-analysis; when it was excluded, the test for heterogeneity did not reach statistical
significance. Why carboplatin was more effective than cisplatin in the Serbian study, in contrast to the results in most of
the other trials, is unknown. However, the patient population (it was younger, had a higher percentage of males and a higher
percentage of stage III cancers than the other studies, and was restricted to patients with squamous histology) and the higher
carboplatin dose [500 versus 325 (<a id="xref-ref-25-9" class="xref-bibr" href="#ref-25">25</a>) or 300 mg/m<sup>2</sup> (<a id="xref-ref-33-11" class="xref-bibr" href="#ref-33">33</a>)] used are factors that may account for this discrepancy. In the remaining eight studies, patient characteristics were very
similar. Five of the studies (<a id="xref-ref-25-10" class="xref-bibr" href="#ref-25">25</a>,<a id="xref-ref-28-9" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-31-12" class="xref-bibr" href="#ref-31">31</a>–<a id="xref-ref-33-12" class="xref-bibr" href="#ref-33">33</a>) showed survival trends in favor of cisplatin, and survival was statistically significantly longer in two of the five (<a id="xref-ref-28-10" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-31-13" class="xref-bibr" href="#ref-31">31</a>). The small study reported by Bisset et al. (<a id="xref-ref-27-10" class="xref-bibr" href="#ref-27">27</a>) showed a survival trend in favor of carboplatin. However, this trial enrolled only 41 patients and combined the platinum
agents with a nonclassical anticancer drug, tirapazamine, which by itself is not active against NSCLC.
</p>
<p id="p-58">Most of the evidence for the equivalence of carboplatin and cisplatin in terms of survival comes from the ECOG 1594 study
(<a id="xref-ref-29-11" class="xref-bibr" href="#ref-29">29</a>). In that four-arm study, 1207 patients were randomly allocated to receive the four most commonly used platinum-based regimens.
Among these, 602 patients were randomly assigned to receive cisplatin (75 mg/m<sup>2</sup> on day 2) combined with paclitaxel (135 mg/m<sup>2</sup> administered for a 24-hour period on day 1) every 3 weeks or carboplatin (AUC 6 on day 1) combined with paclitaxel (225 mg/m<sup>2</sup> for 3-hour period on day 1) every 3 weeks. The different doses and schedules of paclitaxel used in this study may represent
a possible bias for the comparison between cisplatin and carboplatin. Although the 135 mg/m<sup>2</sup> 24-hour infusion and the 225 mg/m<sup>2</sup> 3-hour infusion are supposed to have a comparable efficacy, to our knowledge, no formal clinical comparison between the two
schedules in patients with NSCLC has been reported. The ECOG 1594 study was designed to detect superiority in median survival
of 33% in each of the three experimental arms (including the carboplatin–paclitaxel arm) compared with cisplatin–paclitaxel
(the standard reference arm). Based on the results of ECOG 1594, superiority of the carboplatin–paclitaxel arm was excluded;
however, because the trial was not designed as a noninferiority trial, no conclusion can be drawn about equivalence of the
two regimens.
</p>
<p id="p-59">Another minor bias of this meta-analysis is related to the different doses of cisplatin and carboplatin used in trials that
we analyzed. Cisplatin dose ranged from 75 to 120 mg/m<sup>2</sup>, and carboplatin dose was either based on body surface (ranging from 300 to 500 mg/m<sup>2</sup>) or on AUC (ranging from 5 to 6). However, the platinum dose was always equivalent in the two arms of each study, and it
was rather homogenous in those studies in which third-generation treatments were given (cisplatin dose range = 75–80 mg/m<sup>2</sup> and carboplatin dose range = AUC 5–6). No evidence to date exists of a dose–response effect associated with platinum agents
within the range of the doses used in these studies. Therefore, it is unlikely that these minor differences in platinum doses
affected our findings.
</p>
<p id="p-60">Although the spectrum of toxicity of the two platinum agents was different, the superiority of cisplatin over carboplatin
was not achieved at the cost of a statistically significant increase in the incidence of severe side effects. Carboplatin-based
regimens were associated with more cases of thrombocytopenia of grade 3–4 (12% versus 6%, <em>P</em><.001). Cisplatin-based therapies were associated with more grade 3–4 nausea and vomiting (18% versus 8%; <em>P</em><.001) and nephrotoxicity (1.5% versus 0.5%, <em>P</em> = .018). It is likely that with the recent introduction of newer and more effective antiemetic agents (<a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a>), the 10% higher incidence of severe nausea and vomiting associated with intermediate- to high-dose cisplatin can be ameliorated
further. There was no difference in the rates of neurotoxicity in patients treated with cisplatin compared to those treated
with carboplatin.
</p>
<p id="p-61">Overall, quality of life could not be assessed in our study because only a minority of studies included in the meta-analysis
analyzed this endpoint. However, in the three studies where a formal quality of life assessment was prospectively performed,
there was no statistically significant difference in quality of life that could be attributed to treatment (<a id="xref-ref-28-11" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-31-14" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-33-13" class="xref-bibr" href="#ref-33">33</a>).
</p>
<p id="p-62">Our results are consistent with those of three other meta-analyses that compared carboplatin and cisplatin in NSCLC treatment
and analyzed only published data (<a id="xref-ref-22-2" class="xref-bibr" href="#ref-22">22</a>,<a id="xref-ref-23-2" class="xref-bibr" href="#ref-23">23</a>,<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>). In the only meta-analysis reported in full, Hotta et al. (<a id="xref-ref-22-3" class="xref-bibr" href="#ref-22">22</a>) found, based on analysis of eight trials, that cisplatin-based chemotherapy was superior in terms of response rate (OR =
1.36, 95% CI = 1.15 to 1.61, <em>P</em><.001) but not in terms of survival (HR = 1.050, 95% CI = 0.907 to 1.216, <em>P</em> = .515). In this meta-analysis as well, a statistically significant survival advantage for cisplatin was observed in the
subgroup of third-generation regimens (HR = 1.106, 95% CI = 1.005 to 1.218, <em>P</em> = .039).
</p>
<p id="p-63">Our meta-analysis was conducted on individual patient data and, therefore, it permits us to draw more definite conclusions
than previous analyses, according to the reasons given by Piedbois and Buyse (<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>). In fact, in contrast to meta-analysis based on abstracted data, individual patient data meta-analysis allows the investigator
to evaluate the reliability of the randomization methods, check the trial data, repeat the original analyses (or perform other
ones), and update the patients’ outcomes.
</p>
<p id="p-64">Given the palliative nature of chemotherapy treatment in advanced NSCLC and the unquestionable practical advantage of carboplatin
in terms of ease of administration, it could be argued that the small benefit achieved with cisplatin relative to carboplatin
does not justify its preferential use in clinical practice. However, all the progress in the treatment of advanced NSCLC has
been made in small increments. Particularly, if one considers that the use of platinum-based combination chemotherapy as opposed
to no chemotherapy at all led to only a 27% reduction in the hazard of mortality (<a id="xref-ref-2-2" class="xref-bibr" href="#ref-2">2</a>), the benefit from substituting of one platinum agent for another might not be expected to be higher than that observed in
this meta-analysis. Other drug substitutions, such as the introduction of third-generation agents, have gained success in
clinical practice despite a similarly small benefit (<a id="xref-ref-38-1" class="xref-bibr" href="#ref-38">38</a>). If the results of this meta-analysis may still support the use of carboplatin-based regimens in the palliative treatment
of patients with very advanced disease and/or poor performance status, cisplatin regimens may well be preferable in patients
whose performance status is good and whose disease is less advanced (i.e., oligometastatic stage IV and stage III diseases).
Furthermore, the recent results of the Cancer and Leukemia Group B (CALGB) 9633 adjuvant trial, which was performed in patients
with completely resected stage IB NSCLC and, unlike other recent adjuvant trials (<a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39</a>), showed no benefit of carboplatin–paclitaxel chemotherapy (<a id="xref-ref-40-1" class="xref-bibr" href="#ref-40">40</a>), might be explained by the inferior efficacy of carboplatin observed in our meta-analysis.
</p>
<p id="p-65">In conclusion, based on the results of the randomized trials conducted thus far, our individual patient data meta-analysis,
as well as the previous literature-based meta-analyses, cisplatin should remain the reference platinum agent for treatment
of NSCLC, at least in advanced disease patients with good prognosis and in those with earlier stage disease.
</p>
</div>
<div class="section fn-group" id="fn-group-1">
<div class="section-nav"><a href="#sec-20" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
<h2>Footnotes</h2>
<ul>
<li class="fn" id="fn-13">
<p id="p-66">The granting agencies played no role in the design of the study, the collection of the data, the analysis and interpretation
of the data, the decision to submit the manuscript for publication, or the writing of the manuscript.
</p>
</li>
</ul>
</div>
<ul>
<li class="fn" id="copyright-statement-1">© The Author 2007. Published by Oxford University Press.</li>
</ul>
<div class="section ref-list" id="ref-list-1">
<div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
</div>
<h2>References</h2>
<ol class="cit-list ref-use-labels">
<li><span class="ref-label">(1)</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference (1) in text"
id="ref-1">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.1"
data-doi="10.3322/canjclin.55.1.10">
<div class="cit-metadata">
<ol class="cit-auth-list">
<li><span class="cit-auth"><span class="cit-name-surname">Jemal</span> <span class="cit-name-given-names">A</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Murray</span> <span class="cit-name-given-names">T</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Ward</span> <span class="cit-name-given-names">E</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Samuels</span> <span class="cit-name-given-names">A</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Tiwari</span> <span class="cit-name-given-names">R</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Ghafoor</span> <span class="cit-name-given-names">A</span></span>,
</li>
<li><span class="cit-etal">et al</span></li>
</ol><cite>. <span class="cit-article-title">Cancer statistics, 2005</span>. <abbr class="cit-jnl-abbrev">CA Cancer J Clin</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">55</span>:<span class="cit-fpage">10</span>-<span class="cit-lpage">30</span>.</cite></div>
<div class="cit-extra"><a href="/external-ref?access_num=10.3322/canjclin.55.1.10&link_type=DOI"
class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15661684&link_type=MED"
class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000231483900007&link_type=ISI"
class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
href="http://scholar.google.com/scholar_lookup?title=Cancer%20statistics%2C%202005&author=A%20Jemal&author=T%20Murray&author=E%20Ward&author=A%20Samuels&author=R%20Tiwari&author=A%20Ghafoor&publication_year=2005&journal=CA%20Cancer%20J%20Clin&volume=55&pages=10-30">Google Scholar</a></div>
</div>
</li>
<li><span class="ref-label">(2)</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference (2) in text"
id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.2"
data-doi="10.1136/bmj.311.7010.899">
<div class="cit-metadata"><cite><span class="cit-auth cit-collab">Non-Small Cell Lung Cancer Collaborative Group</span>. <span class="cit-article-title">Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical
trials</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">311</span>:<span class="cit-fpage">899</span>-<span class="cit-lpage">909</span>.</cite></div>
<div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&journalCode=bmj&resid=311/7010/899"
class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
</div>
</li>
<li><span class="ref-label">(3)</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference (3) in text"
id="ref-3">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.3">
<div class="cit-metadata">
<ol class="cit-auth-list">
<li><span class="cit-auth"><span class="cit-name-surname">Cullen</span> <span class="cit-name-given-names">MH</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Billingham</span> <span class="cit-name-given-names">LJ</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Woodroffe</span> <span class="cit-name-given-names">CM</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Chetiyawardana</span> <span class="cit-name-given-names">AD</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Gower</span> <span class="cit-name-given-names">NH</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Joshi</span> <span class="cit-name-given-names">R</span></span>,
</li>
<li><span class="cit-etal">et al</span></li>
</ol><cite>. <span class="cit-article-title">Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>:<span class="cit-fpage">3188</span>-<span class="cit-lpage">94</span>.</cite></div>
<div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&journalCode=jco&resid=17/10/3188"
class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
</div>
</li>
<li><span class="ref-label">(4)</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference (4) in text"
id="ref-4">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.4"
data-doi="10.1038/sj.bjc.6600491">
<div class="cit-metadata">
<ol class="cit-auth-list">
<li><span class="cit-auth"><span class="cit-name-surname">Waters</span> <span class="cit-name-given-names">JS</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">O’Brien</span> <span class="cit-name-given-names">MER</span></span></li>
</ol><cite>. <span class="cit-article-title">The case for the introduction of new chemotherapy agents in the treatment of advanced non-small cell lung cancer in the wake
of the findings of The National Institute of Clinical Excellence (NICE)</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">87</span>:<span class="cit-fpage">481</span>-<span class="cit-lpage">90</span>.</cite></div>
<div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6600491&link_type=DOI"
class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12189541&link_type=MED"
class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000177985400002&link_type=ISI"
class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
href="http://scholar.google.com/scholar_lookup?title=The%20case%20for%20the%20introduction%20of%20new%20chemotherapy%20agents%20in%20the%20treatment%20of%20advanced%20non-small%20cell%20lung%20cancer%20in%20the%20wake%20of%20the%20findings%20of%20The%20National%20Institute%20of%20Clinical%20Excellence%20%28NICE%29&author=JS%20Waters&author=MER%20O%E2%80%99Brien&publication_year=2002&journal=Br%20J%20Cancer&volume=87&pages=481-90">Google Scholar</a></div>
</div>
</li>
<li><span class="ref-label">(5)</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference (5) in text"
id="ref-5">↵</a><div class="cit ref-cit ref-book" id="cit-99.11.847.5"
data-doi="10.1200/JCO.2004.09.053">
<div class="cit-metadata">
<ol class="cit-auth-list">
<li><span class="cit-auth"><span class="cit-name-surname">Pfister</span> <span class="cit-name-given-names">DG</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Johnson</span> <span class="cit-name-given-names">DH</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Azzoli</span> <span class="cit-name-given-names">CG</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Sause</span> <span class="cit-name-given-names">W</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Smith</span> <span class="cit-name-given-names">TJ</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Baker</span> <span class="cit-name-given-names">S</span> <span class="cit-name-suffix">Jr</span></span>,
</li>
<li><span class="cit-etal">et al</span></li>
</ol><cite>. <span class="cit-source">J Clin Oncol</span>. Vol. <span class="cit-vol">22</span>. <span class="cit-pub-date">2004</span>. <span class="cit-article-title">American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003</span>; p. <span class="cit-fpage">330</span>-<span class="cit-lpage">53</span>.</cite></div>
<div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&journalCode=jco&resid=22/2/330"
class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
</div>
</li>
<li><span class="ref-label">(6)</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference (6) in text"
id="ref-6">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.6">
<div class="cit-metadata">
<ol class="cit-auth-list">
<li><span class="cit-auth"><span class="cit-name-surname">Evans</span> <span class="cit-name-given-names">WK</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Newman</span> <span class="cit-name-given-names">T</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Graham</span> <span class="cit-name-given-names">I</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Rusthoven</span> <span class="cit-name-given-names">JJ</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Logan</span> <span class="cit-name-given-names">D</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Shepherd</span> <span class="cit-name-given-names">FA</span></span>,
</li>
<li><span class="cit-etal">et al</span></li>
</ol><cite>. <span class="cit-article-title">Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1997</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">3049</span>-<span class="cit-lpage">59</span>.</cite></div>
<div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&journalCode=jco&resid=15/9/3049"
class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
</div>
</li>
<li><span class="ref-label">(7)</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference (7) in text"
id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-99.11.847.7"
data-doi="10.1093/annonc/mdi821">
<div class="cit-metadata">
<ol class="cit-auth-list">
<li><span class="cit-auth"><span class="cit-name-surname">Felip</span> <span class="cit-name-given-names">E</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Stahel</span> <span class="cit-name-given-names">RA</span></span>,
</li>
<li><span class="cit-auth"><span class="cit-name-surname">Pavlidis</span> <span class="cit-name-given-names">N</span></span></li>
</ol><cite>. <span class="cit-article-title">ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">16</span>:<span class="cit-fpage">i28</span>-<span class="cit-lpage">9</span>.</cite></div>